Tooth decay is the most common health condition worldwide. While it is preventable and treatable, billions of people are living with cavities and the pain that accompanies them.
A new study from Karolinska Institutet, published in the journal The BMJ, shows how a simple blood analysis can predict the risk of developing severe liver disease. The method may already start to be applied in primary care to enable the earlier detection of cirrhosis and cancer of the liver.
A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments.
iTaperloc Complete and iG7 Hip System with Iodine Technology inhibits bacterial adhesion and prevents biofilm formation on the implant surface to help address the issue of Periprosthetic Joint Infection after total joint replacement
Alzheimer’s disease is marked by the buildup of amyloid plaques in the brain, but most ways of studying these deposits in mouse models require sacrificing the animals. That limits researchers’ ability to follow how the disease develops or how treatments work over time.
Could a simple blood test reveal how well someone is aging?
Investigators saw a 71% reduction in myopia progression in children who used the lenses for two years.
AngioSafe announced it has received FDA 510(k) clearance and CE marking for its Santreva-ATK endovascular revascularization catheter.
MADISON, Wis., Sept. 26, 2025 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) announced today that the company is advancing its legacy of leadership in adaptive radiotherapy with the introduction of the Accuray Stellar™* Solution. Initially for the U.S. market, the new Accuray technology is not just a system, it’s a solution, comprised of a comprehensive tool set designed to empower clinical teams to address the evolving treatment needs of patients undergoing radiotherapy.
The newly issued patent strengthens Nexalin’s expanding intellectual property estate, supporting the Company’s DIFS platform and ongoing clinical and regulatory initiatives